High-throughput qRT-PCR validation of blood microRNAs in non-small cell lung cancer. Leidinger, P., Brefort, T., Backes, C., Krapp, M., Galata, V., Beier, M., Kohlhaas, J., Huwer, H., Meese, E., & Keller, A. Oncotarget, 7:4611–4623, January, 2016.
doi  abstract   bibtex   
Validation of biomarkers is essential to advance the translational process to clinical application. Although there exists an increasing number of reports on small non-coding RNAs (microRNAs) as minimally-invasive markers from blood, serum or plasma, just a limited number is verified in follow-up studies. We used qRT-PCR to evaluate a known miRNA signature measured from blood that allowed for separation between patients with non-small cell lung cancer (NSCLC), COPD and healthy controls.From the data of our previous microarray studies we selected a panel of 235 miRNAs related to lung cancer and COPD. We observed a high concordance between the AUC values of our initial microarray screening and the qRT-PCR data (correlation of 0.704, p < 10-16). Overall, 90.3% of markers were successfully validated. Among the top markers that were concordant between both studies we found hsa-miR-20b-5p, hsa-miR-20a-5p, hsa-miR-17-5p, and hsa-miR-106a-5p. The qRT-PCR analysis also confirmed that non-small cell lung cancer patients could be accurately differentiated from unaffected controls: a subset of five markers was sufficient to separate NSCLC patients from unaffected controls with accuracy of 94.5% (specificity and sensitivity of 98% and 91%). Beyond differentiation from controls, we also succeeded in separating NSCLC patients from patients with COPD. MiRNAs that were identified as relevant for the separation between lung cancer and COPD by both qRT-PCR and the array-based studies included hsa-miR-26a-5p, hsa-miR-328-3p and hsa-miR-1224-3p. Although for differentiation between NSCLC patients from COPD patients more markers were required, still high accuracy rates were obtained (5 markers: 78.8%; 10 markers: 83.9%; 50 markers: 87.6%).
@Article{Leidinger2016,
  author          = {Leidinger, Petra and Brefort, Thomas and Backes, Christina and Krapp, Medea and Galata, Valentina and Beier, Markus and Kohlhaas, Jochen and Huwer, Hanno and Meese, Eckart and Keller, Andreas},
  title           = {High-throughput qRT-PCR validation of blood microRNAs in non-small cell lung cancer.},
  journal         = {Oncotarget},
  year            = {2016},
  volume          = {7},
  pages           = {4611--4623},
  month           = jan,
  issn            = {1949-2553},
  abstract        = {Validation of biomarkers is essential to advance the translational process to clinical application. Although there exists an increasing number of reports on small non-coding RNAs (microRNAs) as minimally-invasive markers from blood, serum or plasma, just a limited number is verified in follow-up studies. We used qRT-PCR to evaluate a known miRNA signature measured from blood that allowed for separation between patients with non-small cell lung cancer (NSCLC), COPD and healthy controls.From the data of our previous microarray studies we selected a panel of 235 miRNAs related to lung cancer and COPD. We observed a high concordance between the AUC values of our initial microarray screening and the qRT-PCR data (correlation of 0.704, p < 10-16). Overall, 90.3% of markers were successfully validated. Among the top markers that were concordant between both studies we found hsa-miR-20b-5p, hsa-miR-20a-5p, hsa-miR-17-5p, and hsa-miR-106a-5p. The qRT-PCR analysis also confirmed that non-small cell lung cancer patients could be accurately differentiated from unaffected controls: a subset of five markers was sufficient to separate NSCLC patients from unaffected controls with accuracy of 94.5% (specificity and sensitivity of 98% and 91%). Beyond differentiation from controls, we also succeeded in separating NSCLC patients from patients with COPD. MiRNAs that were identified as relevant for the separation between lung cancer and COPD by both qRT-PCR and the array-based studies included hsa-miR-26a-5p, hsa-miR-328-3p and hsa-miR-1224-3p. Although for differentiation between NSCLC patients from COPD patients more markers were required, still high accuracy rates were obtained (5 markers: 78.8%; 10 markers: 83.9%; 50 markers: 87.6%).},
  chemicals       = {Biomarkers, Tumor, MicroRNAs, RNA, Messenger},
  citation-subset = {IM},
  completed       = {2016-10-27},
  country         = {United States},
  doi             = {10.18632/oncotarget.6566},
  issn-linking    = {1949-2553},
  issue           = {4},
  keywords        = {Aged; Biomarkers, Tumor, blood, genetics; Carcinoma, Non-Small-Cell Lung, blood, genetics; Case-Control Studies; Cohort Studies; Female; Gene Expression Profiling; High-Throughput Screening Assays; Humans; Lung Neoplasms, blood, genetics; Male; MicroRNAs, blood, genetics; Middle Aged; Prognosis; Pulmonary Disease, Chronic Obstructive, blood, genetics; RNA, Messenger, genetics; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; NSCLC; diagnosis; miRNA; qRT-PCR},
  nlm-id          = {101532965},
  owner           = {NLM},
  pii             = {6566},
  pmc             = {PMC4826230},
  pmid            = {26672767},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2017-02-20},
}
Downloads: 0
About
Documentation
Keywords
Search
Users
Terms and Conditions of Use
Privacy Policy
Sitemap
© BibBase.org 2021